the SPRINT Study Group Background and Purpose: Stroke complicating acute myocardial infarction is associated with substantial morbidity and mortality. The purpose of this study was to assess the incidence, predictors, and impact on
Stroke is a serious potential complication of acute myocardial infarction (AMI). Several publications have outlined the incidence and clinical significance of stroke occurring during AMI in the prethrombolyticl-4 and thrombolytic eras.5-13 The frequency of this complication has apparently not increased with the advent of thrombolytic treatment but nevertheless remains an important cause of morbidity and mortality in patients with AMI. Data on the incidence and prognostic significance of stroke in survivors from AMI, however, are very scarce and limited to select subgroups of patients.14- 17 The purposes of the present study were (1) to assess the incidence of stroke or transient ischemic attack (TIA) after hospital discharge in a large unselected population of survivors from AMI, (2) to identify the characteristics of MI patients at risk, and (3) to assess the impact on mortality of stroke/TIA occurring after AMI.
Materials and Methods
From August 1981 to July 1983, 4808 hospital survivors from a cohort of 5839 consecutive AMI patients hospitalized in 13 of the 21 existing coronary care units in Israel were screened for inclusion in SPRINT (Secondary Prevention Reinfarction Israeli Nifedipine Trial). No effect of nifedipine on mortality or reinfarction after AMI was observed during the trial. '8 Demographic, historical, and clinical data were collected on study forms for all registered AMI patients by the study physicians in the coronary care units. Historical characteristics were based on self report by patients at the time of hospitalization. The diagnosis of AMI was based on the presence of typical symptoms, including severe pain in the region of the sternum, the precordium, or the upper abdomen lasting for at least 1 
Statistical Analysis
The prevalence of attributes correlating with stroke/ TIA was compared between patients with and without stroke/TIA, and the differences were examined by the X2 test. Mortality rates were adjusted for age according to the total study distribution in age groups of c50 years, 50 to 69, and >70 years. By exponentiating risk coefficients derived from multiple logistic regression, we obtained estimates20 of the covariate-adjusted relative odds for the associated with presence versus absence of chronic atrial fibrillation; past MI; anterior MI site; past stroke; GOT level more than four times above upper normal limit; and for a 10-year age increment (namely, the factors that significantly predicted the incidence of stroke/TIA). The SAS software was used,2' specifically the FREQ and CAT-MOD procedures for this analysis. The actuarial survival curves were computed by the LIFETEST procedure.
Results Forty-eight (1%) of the 4808 hospital survivors from AMI experienced stroke/TIA in the year after the MI. Thirty-seven of these cases were diagnosed as stroke and 11 as TIA. Rates did not differ significantly among men (0.9%) and women (1.3%). However, rates were significantly elevated among older patients (>70 years, 1.9%) and in those with a history of previous MI (1.8%), hypertension (1.4%), stroke in the past (4.1%), or chronic atrial fibrillation (9%) in comparison with younger patients (c50 years; 0.5%; P<.001), patients with a first MI (0.8%; P<.01), and in those free of hypertension (0.7%; P=.06), previous stroke (0.9%; P<.001), or chronic atrial fibrillation (1%, P<.001). Thirty-one percent (15 of 48) of events occurred in the first month and 63% (30 of 48) during the first half year after hospital discharge. The characteristics and hospital course of patients with and without stroke/TIA in the year after the MI are given in Tables 1 and 2 . Patients developing stroke/TIA were 6 years older and more often had a past history of MI, hypertension, chronic atrial fibrillation, or stroke. However, a past history of angina pectoris, diabetes mellitus, or smoking were nearly equally prevalent in both groups. Anterior site of MI and high levels of the cardiac enzyme GOT were more frequent in patients subsequently developing stroke/TIA. Patients who developed stroke/TIA presented more often in a higher Killip class and had pulmonary congestion or edema on admission more often than counterparts without stroke/TIA. All other in-hospital complications were nearly equally prevalent in both groups ( Table 2 ). The age-adjusted 1-year and long-term mortality rates (4.5 to 7 years; mean, 5.5 years) were significantly higher in patients with stroke/ TIA (Table 3 ) than in those without (31% and 62% vs 9% and 31%, respectively; P<.01). Fourteen of the 19 deaths (74%) that occurred during the first year among patients with stroke/TIA occurred within 2 weeks of the cerebral event. Figure 1 shows the respective survival curves of patients with and without stroke/TIA.
At discharge from the hospital, 13 patients (27%) who subsequently developed stroke/TIA and 759 patients (16%) in the reference group received anticoagulant or antiaggregant drugs.
To assess the independent parameters predicting the appearance of stroke/TIA in the year after AMI, multivariate analysis was conducted among 4808 survivors adjusting for the following: age, gender, past history of MI, angina pectoris, hypertension, diabetes mellitus, chronic atrial fibrillation, previous stroke, smoking, anterior MI site, congestive heart failure on admission to hospital, pulmonary congestion, or cardiomegaly on chest x-ray, as well as in-hospital complications including congestive heart failure, paroxysmal atrial fibrillation, ventricular arrhythmia, advanced atrioventricular occurrence of stroke/TIA during the year after AMI, block, and high serum enzyme levels. The independent (Table 4) . Taking into account the six risk factors, the estimated likelihood of developing stroke/TIA in hospital survivors from AMI rose from 0.29% in patients without any risk factors to 3.18% among patients with three and 6.76% among patients with four of the above risk factors (Fig 2) . None of the patients had more than four risk factors. Cl, confidence interval; Ml, myocardial infarction; GOT, glutamic oxaloacetic transaminase.
follow-up. In a more recent trial17 on the effect of warfarin after MI, 44 of 607 (7%) patients experienced stroke in the placebo arm of the study during an average follow-up time of 37 months.
The incidence of stroke in the general population was evaluated extensively in the population of Rochester, Minn. 22 The average annual age and sex adjusted incidence of stroke was 0.14% for the years 1980 to 1984 (0.21% for the 55-to 64-year-old group). In the Jewish population of northern Israel, the incidence of stroke in 1984 was higher: the age standardized incidence rates were 0.61% and 0.50% for men and women, respectively (for the 60-to 64-year-old group, 0.56% and 0.49%, respectively).23 Thus, although the incidence of stroke is relatively low in the year after the acute phase of MI, it nevertheless remains higher in comparison with the general population.
Clinical Predictors of Stroke
The most reliable predictors of stroke during AMI as previously reported by our group and others were older age, anterior site of MI, high enzyme levels, impaired *X.. To the best of our knowledge the clinical factors associated with increased risk of stroke in patients after discharge from AMI were not previously assessed. In the present study the factors identified as contributing independently to increased risk of stroke/TIA after hospital discharge were chronic atrial fibrillation, older age, past MI, anterior site of MI, serum GOT levels more than four times above upper normal limits, and previous stroke. The likelihood of developing stroke/ TIA after hospital discharge increased proportionally to the number of risk factors present.
Chronic atrial fibrillation was present in 6% (3 of 48) of stroke/TIA patients versus less than 1% (32 of 4760) of the reference group. In a previous study we reported that chronic atrial fibrillation increased the risk of subsequent stroke/TIA ninefold. 24 In several studies, nonrheumatic chronic atrial fibrillation was associated with approximately fivefold increased risk for stroke in comparison with matched population with sinus rhythm.25,26 Moreover, low intensity anticoagulation with warfarin can prevent most of the additional stroke risks caused by atrial fibrillation. 27 Echocardiographic studies have shown that the majority of patients with visible mural thrombi have had an anterior infarction, whereas patients with good left ventricular function and inferior infarction rarely had detectable thrombi. Mural thrombi are known to be associated with an increased embolic risk in the first few weeks after acute MI; however, there are conflicting results regarding their long-term embolic risk.28-30 Weinreich and coworkers28 followed 43 patients with left ventricular thrombi after AMI and identified embolic events only during the first 4 months after infarction in a mean follow-up of 15 months. However, in a more recent prospective study, following 85 patients with left ventricular thrombi, all embolic events occurred later than 1 month after MI (range, 1 to 96 months), suggesting that chronic thrombi continue to embolize.29 In the SPRINT Registry echocardiogram was not routinely performed on all hospital survivors. However, anterior site of MI was found to independently increase the risk of stroke after AMI.
Clinical Implications
The mortality of patients developing stroke during hospitalization for AMI is very high. We3 and others8'9 have previously reported an estimated threefold inhospital mortality among patients with stroke/TIA during AMI in comparison to those without. Mortality was also significantly elevated among the 48 patients of this study who developed stroke/TIA after discharge. The majority of deaths up to an average of 5.5 years after discharge in those patients occurred during the first year of follow-up. Moreover, nearly three quarters of the deaths during the first year (14 of 19) occurred within 2 weeks of the cerebral event.
Long-term anticoagulant treatment possibly has a favorable effect on the incidence of stroke after acute MI,17 although associated with a variable degree of hemorrhagic complications. Identification of high versus low risk patients for stroke might help in the selection of patients who could benefit most from this treatment. 
